The AMIBM’s significance for external (Eu)regional key stakeholders is of great importance.
AMIBM scientists work closely with companies and public-private partnerships in the (Eu)region. Within the Brightlands Chemelot Campus ecosystem, the AMIBM works closely with DSM (Materials Science Center), SABIC, GF Biochemicals and Sitech, and in public-private partnerships with Chemelot InSciTe, Centre of Expertise Chemelot Innovation and Learning Labs (CHILL), Brightlands Materials Center and the new initiative Brightsite.
The AMIBM also has crossovers with institutions located on other Brightlands campuses in Limburg, such as the Institute for Technology-Inspired Regenerative Medicine (MERLN) at Brightlands Maastricht Health Campus, and the BioTreat Center at Brightlands Campus Venlo.
Because the AMIBM was established with RWTH-Aachen University and has developed as a European cross-border research institute, there are close collaborations with the Institute of Applied Medical Engineering (AME), and the Center for Biohybrid Medical Systems, in particular, as well as the Fraunhofer IME and DWI Leibniz Institute for Interactive Materials.
Furthermore, the AMIBM works together with more than 50 industrial partners. This large network of institutes, companies and public-private partnerships has led to many new projects in which the AMIBM is a participant or coordinator.
All these accomplishments underline the importance and significance of AMIBM for external regional key stakeholders.